Pharmacokinetics of the inodilator XB513 in mice, rats, guinea pigs, rabbits, dogs, and monkeys.
Stampfli
H F
HF
DuPont Merck Pharmaceutical Company, Drug Metabolism and Pharmacokinetics Section, Stine-Haskell Research Center, Newark, DE 19714.
Person
C R
CR
Huang
S M
SM
Quon
C Y
CY
D000818:Animals; D001682:Biological Availability; D002120:Calcium Channel Agonists / Q000493:pharmacokinetics*; D002851:Chromatography, High Pressure Liquid; D004095:Dihydropyridines / Q000493:pharmacokinetics*; D004285:Dogs; D005260:Female; D006168:Guinea Pigs; D008252:Macaca fascicularis; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D010879:Piperazines / Q000493:pharmacokinetics*; D011817:Rabbits; D051381:Rats; D013045:Species Specificity
D002120:Calcium Channel Agonists; D004095:Dihydropyridines; D010879:Piperazines; C081663:XB 513